**Background of CD118 Antibody**
The CD118 antibody targets the CD118 antigen, a cell surface protein also known as the **leukemia inhibitory factor receptor beta (LIFRβ)**. CD118 is a subunit of the LIF receptor complex, which forms a heterodimer with glycoprotein 130 (gp130), a shared signal-transducing component of the interleukin-6 (IL-6) cytokine family. This receptor plays a critical role in mediating cellular responses to ligands like leukemia inhibitory factor (LIF) and oncostatin M (OSM), regulating processes such as cell differentiation, proliferation, and survival.
CD118 is expressed in various tissues, including immune cells, neurons, and stem cells, and is implicated in embryonic development, neurogenesis, and immune regulation. Dysregulation of LIFR signaling has been linked to cancer progression, inflammatory diseases, and neurodegenerative conditions.
CD118 antibodies are essential tools for studying receptor localization, expression levels, and signaling mechanisms. They are widely used in **immunohistochemistry (IHC)**, **flow cytometry**, and **Western blotting** to investigate LIFRβ's role in disease models or therapeutic contexts. In cancer research, CD118 antibodies help explore its dual role as both a tumor suppressor and promoter, depending on cellular context. Additionally, they support the development of targeted therapies, such as blocking antibodies or ligand traps, to modulate LIFR-mediated pathways in autoimmune disorders or malignancies.
Overall, CD118 antibodies provide valuable insights into the biology of cytokine receptors and their translational potential in medicine.